利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

499 records (took 0.031 seconds)

    TREATMENT OF AN IOP CONDITION
    4.
    发明公开
    TREATMENT OF AN IOP CONDITION 审中-公开

    公开(公告)号：US20240115672A1

    公开(公告)日：2024-04-11

    申请号：US18546236

    申请日：2022-02-11

    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

    Inventor： Ioannis (John) DANIAS

    IPC: A61K38/49 ,  A61K9/00 ,  A61P27/06

    CPC classification number: A61K38/49 ,  A61K9/0048 ,  A61P27/06 ,  C12Y304/21068

    Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.

    Combination therapy for ischemia
    5.
    发明授权
    Combination therapy for ischemia 有权

    公开(公告)号：US11878044B2

    公开(公告)日：2024-01-23

    申请号：US17177970

    申请日：2021-02-17

    Applicant: NoNO Inc.

    Inventor： Michael Tymianski

    IPC: A61K38/10 ,  A61K38/49 ,  A61K38/17

    CPC classification number: A61K38/10 ,  A61K38/1787 ,  A61K38/49 ,  A61K38/1787 ,  A61K2300/00 ,  A61K38/49 ,  A61K2300/00

    Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.

    TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS
    10.
    发明申请
    TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS 有权

    公开(公告)号：US20220218639A1

    公开(公告)日：2022-07-14

    申请号：US17529420

    申请日：2021-11-18

    Applicant: Indiana University Research and Technology Corporation

    Inventor： Jeffrey A. Kline ,  Nathan J. Alves ,  Daren M. Beam

    IPC: A61K31/196 ,  A61K38/48 ,  A61K38/49 ,  A61K47/69 ,  A61K47/54 ,  A61K45/06

    Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Patent Agency Ranking